Press Releases October 9, 2026 07:00 AM

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Balchem Corporation schedules Q3 2026 earnings conference call for October 23, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
BCPC

Balchem Corporation announced it will hold a conference call on October 23, 2026, to discuss its third quarter financial results. The company's leadership, including CEO Ted Harris and CFO Martin Bengtsson, will host the call. Results and financial exhibits will be published prior to the call and available on Balchem's website. The company operates in specialty ingredients across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments.

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
BCPC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Balchem will report Q3 2026 financial results on October 23, 2026, before market open.
  • The company serves diverse sectors including food, supplements, pharmaceuticals, animal health, and specialty chemicals.
  • Conference call to be hosted by top executives, offering insights into performance and outlook.

MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call.

Third quarter results will be published prior to the market opening on Friday, October 23, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call.

Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.

About Balchem Corporation

Balchem Corporation develops, manufactures, and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement, and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.

Contact:Jacqueline Yarmolowicz, Executive Assistant Telephone: 845-326-5600 E-mail: [email protected]



Risks

  • Quarterly results may reveal challenges in key business segments affecting investor confidence.
  • Market conditions in food, nutrition, animal health, and specialty chemical sectors could impact revenue growth.
  • Dependence on global supply chains and regulatory environments may create operational uncertainties.

More from Press Releases

Edible Garden Receives Preliminary Approval to Sell Tax Credits Through New Jersey Economic Development Authority (NJEDA) Program Oct 9, 2026 High Roller Technologies to Present at the 2026 ThinkEquity Conference Oct 9, 2026 SkinHealth Systems Announces Reverse Stock Split Oct 9, 2026 Gentherm Announces Date for 2026 Third Quarter News Release and Conference Call Oct 9, 2026 HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors Oct 9, 2026